Cheng, A., Qin, S., Ikeda, M., Galle, P., Ducreux, M., Zhu, A., Kim, T., Kudo, M., Breder, V., Merle, P., Kaseb, A., Li, D., Verret, W., Xu, Z., Hernandez, S., Liu, J., Huang, C., Mulla, S., Lim, H. Y., & Finn, R. (n.d.). lBA3IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). Annals of oncology, 30, . http://access.bl.uk/ark:/81055/vdc_100098039644.0x00002c